BMI Tables for Females: NHS Ranges Explained

BMI tables for females are a widely used starting point for assessing whether a woman's weight falls within a healthy range. Body mass index is calculated by dividing weight in kilograms by height in metres squared, and NHS-aligned tables display results across four colour-coded categories: underweight, healthy weight, overweight and obese. While the same formula applies to both sexes, women typically carry a higher proportion of body fat at any given BMI, so clinicians often consider additional measures such as waist circumference alongside the table result. This guide explains how to read BMI tables, what the NHS numbers mean for women, and when to seek clinical advice.

How do you read a BMI table as a woman?

Locate your height and weight on the table axes and find where they intersect to identify your BMI category. Women from certain ethnic backgrounds may face health risks at lower BMI thresholds, so discuss results with a GP if uncertain.

To read a BMI table as a woman, locate your height along one axis and your weight along the other, then find where the two values intersect to identify your BMI category. BMI, or body mass index, is calculated by dividing weight in kilograms by height in metres squared. Most NHS-aligned BMI tables display results in colour-coded bands, making it straightforward to see whether a result falls into the underweight, healthy weight, overweight or obese range.

Adult BMI tables are designed for people aged 18 and over. They should not be used to assess weight in children or young people under 18, for whom separate paediatric assessment tools are used; a GP or school nurse can advise on the appropriate approach for younger individuals.

It is important to understand that BMI tables apply the same calculation to both men and women, so there is no separate mathematical formula for females. However, because women typically carry a higher proportion of body fat than men at the same BMI, some clinicians consider additional measurements alongside BMI to build a fuller picture of health risk. The NHS recommends also measuring waist circumference: a waist measurement above 80 cm (31.5 inches) in women is considered to indicate increased health risk, and above 88 cm (34.5 inches) indicates high risk.

For women from some ethnic groups, including South Asian, Chinese, Black African and Middle Eastern backgrounds, the NHS notes that health risks associated with excess weight may occur at lower BMI thresholds. NICE guidance acknowledges that a BMI of 23 or above may indicate increased risk, and a BMI of 27.5 or above may indicate high risk, in these groups. When using a BMI table, it is worth bearing this context in mind and discussing results with a GP if there is any uncertainty about what the figure means for individual health.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, and is one option for women seeking clinical guidance alongside their BMI assessment.

BMI Ranges for Women: What the NHS Numbers Mean

The NHS defines four adult BMI categories: underweight (below 18.5), healthy weight (18.5 to 24.9), overweight (25 to 29.9) and obese (30 or above), with obesity further subdivided into three classes linked to clinical eligibility criteria.

The NHS uses four standard BMI categories for adults, including women: underweight (below 18.5), healthy weight (18.5 to 24.9), overweight (25 to 29.9) and obese (30 or above). These thresholds are consistent with World Health Organization classifications and form the basis of clinical decision-making in primary care across the UK.

Within the obese category, the NHS further subdivides results into three classes:

• Class I (moderate): BMI 30 to 34.9

• Class II (severe): BMI 35 to 39.9

• Class III (very severe obesity): BMI 40 or above

These subdivisions matter clinically because eligibility for certain interventions, including referral to specialist weight-management services or consideration of pharmacological treatment, is often linked to specific BMI thresholds under NICE guidance. For example, NICE technology appraisals for weight-management medicines specify BMI criteria that clinicians must consider alongside other clinical factors before recommending treatment.^[5][6]

It is also worth noting that BMI has recognised limitations as a measure. In people with a high muscle mass, for example, BMI may overestimate body fat, while in older adults it may underestimate it. For this reason, clinicians typically consider BMI alongside other measures, such as waist circumference, when assessing health risk.

For women who are pregnant, BMI tables should be interpreted with caution. Weight gain during pregnancy is expected and healthy, and standard adult BMI categories are not designed to be applied during pregnancy. Women who are pregnant should discuss weight-related concerns with their midwife or obstetric team rather than relying on a general BMI table.

It is also worth noting that BMI is a screening tool rather than a diagnostic measure. A result outside the healthy range prompts further assessment rather than an automatic diagnosis, and a GP can help interpret what a BMI figure means in the context of an individual woman's overall health.

What health risks are linked to a high or low BMI in women?

A high BMI is associated with type 2 diabetes, cardiovascular disease, PCOS and certain cancers, while a BMI below 18.5 in women is linked to amenorrhoea, reduced bone density and fertility difficulties.

A BMI consistently outside the healthy range is associated with a range of health risks in women, with both high and low values carrying distinct clinical concerns. A BMI in the overweight or obese range is linked to increased risk of type 2 diabetes, cardiovascular disease, certain cancers (including breast and endometrial cancer), polycystic ovary syndrome (PCOS), sleep apnoea and musculoskeletal problems.^[7][25] The risk generally increases as BMI rises, particularly above 30.

For women specifically, excess weight can affect hormonal balance and reproductive health. PCOS, which affects a significant proportion of women of reproductive age, is closely associated with insulin resistance and is more common in women with a higher BMI.^[23][24] Fertility can also be affected, and NICE guidance on fertility treatment includes BMI thresholds as part of eligibility criteria for certain assisted conception procedures.^[28][29]

At the other end of the scale, a BMI below 18.5 carries its own risks. In women, a low BMI is associated with menstrual irregularity or absence (amenorrhoea), reduced bone density and increased risk of osteoporosis, nutritional deficiencies and impaired immune function.^[8][9] Women with a very low BMI may also experience difficulties conceiving.

Women who notice a significant or unexplained change in their BMI, whether upward or downward, should speak to their GP. Unexplained weight loss in particular warrants prompt medical review, as it can occasionally indicate an underlying condition requiring investigation. For urgent concerns, NHS 111 can provide advice, while a GP appointment is the appropriate route for non-urgent assessment and ongoing management.

How can women reach and maintain a healthy BMI?

UK guidelines recommend at least 150 minutes of moderate aerobic activity weekly alongside a balanced diet; where lifestyle changes are insufficient, NICE-recommended prescription medicines such as semaglutide or tirzepatide may be considered with clinical support.

Women can work towards a healthy BMI through a combination of balanced nutrition, regular physical activity and, where appropriate, clinical support. UK Chief Medical Officers' guidelines recommend that adults aim for at least 150 minutes of moderate-intensity aerobic activity per week, alongside strength-based exercise on two or more days.^[11][12] Dietary approaches that emphasise vegetables, wholegrains, lean protein and reduced intake of ultra-processed foods are consistently supported by evidence and align with NHS Eatwell Guide principles.

For women whose BMI falls into the overweight or obese range and who have not achieved sufficient progress through lifestyle changes alone, NICE recommends that clinicians consider referral to structured weight-management programmes. In some cases, pharmacological treatment may be appropriate. Medicines currently authorised by the MHRA for chronic weight management in the UK include semaglutide (Wegovy, available as both a subcutaneous injection and as Wegovy 25 mg tablets, the oral formulation authorised by the MHRA in June 2026), tirzepatide (Mounjaro), orforglipron (Foundayo) and liraglutide (Saxenda).^[15] NICE technology appraisals specifically recommend semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight management within defined eligibility criteria; liraglutide (Saxenda) and orforglipron (Foundayo) do not currently have equivalent NICE weight-management technology appraisals, and their availability on the NHS will depend on local Integrated Care Board (ICB) commissioning decisions and individual clinical assessment.^[13][14] Orlistat is also available as a longer-established option and may be considered in some circumstances. All of these medicines are prescription-only and require a clinical consultation before they can be prescribed. None are suitable for use during pregnancy or breastfeeding, and women of childbearing potential should discuss contraception with their prescriber before starting treatment.

Maintaining a healthy BMI over the long term requires sustainable habits rather than short-term restriction. Regular monitoring, support from a healthcare professional and addressing underlying factors such as sleep quality, stress and mental health all contribute to lasting results. Women who feel their weight is affecting their quality of life are encouraged to speak to their GP as a first step, who can assess individual circumstances and discuss the most appropriate pathway forward.

Scientific References

1. Overweight and obesity management – Identifying and assessing overweight, obesity and central adiposity (NG246).
2. Calculate your body mass index (BMI) for adults.
3. Calculate your body mass index (BMI).
4. Obesity – Treatment summaries, BNF.
5. Overweight and obesity management – Medicines and surgery (NG246).
6. A guide for prescribing medicines to manage overweight and obesity (TA1026 resource).
7. Overweight and obesity in adults.
8. The association between body mass index and osteoporosis. Asomaning K et al..
9. Food Versus Pharmacy: Assessment of Nutritional and Pharmacological Strategies to Improve Bone Health in Energy-Deficient Exercising Women. Current Osteoporosis Reports..
10. Energy balance, bone turnover, and skeletal health in physically active individuals. Medicine and Science in Sports and Exercise..
11. Physical activity guidelines: UK Chief Medical Officers' report.
12. Physical activity guidelines for adults aged 19 to 64.
13. Semaglutide for managing overweight and obesity (TA875).
14. Tirzepatide for managing overweight and obesity (TA1026).
15. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
16. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
17. First GLP-1 tablet for weight loss approved in the UK (semaglutide/Wegovy oral).
18. Liraglutide for managing overweight and obesity (TA664).
19. Liraglutide: a medicine to treat type 2 diabetes or obesity.
20. Calculate your waist to height ratio.
21. Body mass index and waist circumference cut-points in multi-ethnic populations from the UK and India. PLoS One..
22. Nutrition in an ethnically diverse society: what are some of the key challenges? Proceedings of the Nutrition Society..
23. Polyendocrine metabolic ovarian syndrome (PMOS) and diet.
24. Polyendocrine metabolic ovarian syndrome (PMOS).
25. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Systematic Reviews..
26. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews..
27. Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis. Human Reproduction..
28. Access criteria for in vitro fertilisation (IVF) – Fertility problems (NG257).
29. NHS-funded in vitro fertilisation (IVF) in England.
30. Osteoporosis – Causes.

Frequently Asked Questions